Qilu Pharma Starts China Bridging Trial for Bladder Cancer Drug
July 21, 2021 at 06:24 AM EDT
Jilin Qilu Pharmaceutical has enrolled the first patient in a China bridging trial of Vicineum in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). One year ago, Qilu in-licensed China rights to the candidate from Boston 's Sesen Bio in a deal worth $38 million. The start of the trial triggered a $3 million milestone payment. Sesen develops targeted fusion protein therapeutics for cancer. Qilu expects to submit a China market application for Vicineum in 2022; a decision on Sesen's application for US marketing approval is due in August. More details.... Stock Symbol: (NSDQ: SESN) Share this with colleagues: // //
